Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Sun, September 6, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Sun, August 30, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Sun, August 2, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009

Spring Creek Capital Corporation: Spring Creek Capital Corporation (OTCBB: SCRK) Engages Renowned Biotech Patent Attorney to Se


//stocks-investing.news-articles.net/content/200 .. ages-renowned-biotech-patent-attorney-to-se.html
Published in Stocks and Investing on , Last Modified on 2009-08-20 12:37:19 by Market Wire   Print publication without navigation


NEW YORK, NY--(Marketwire - August 20, 2009) - Spring Creek Capital Corporation (OTCBB: [ SCRK ]) announced today that it has engaged Jennifer McCallum of the McCallum Law Firm in Erie, Colorado to serve as corporate counsel of its newly formed stem cell company AllStem.

Ms. McCallum is a patent attorney with a Ph.D. in Biotechnology from Colorado State University and a J.D. from the University of Colorado. She has received numerous awards and accolades in her field, including a 2008 Congressional Medal of Distinction and an appointment by Governor Owens to the Biotechnology Council for the State of Colorado. In addition, Jennifer has received four appointments as the Vice-Chair of the American Bar Association's Committee on Bioethics, and she was one of seven attorneys sponsored in 2006 by the American Bar Association for an in-person en banc lifetime admission to the US Supreme Court. In 2009, she was named one of the Rising Stars in the US legal field by Super Lawyers. Jennifer has extensive international licensing and patenting experience and has a network of 120 affiliate law firms worldwide. She is a highly sought after speaker providing rare insight into complex legal and scientific issues largely centering around pharmaceuticals and stem cell sciences.

According to Kelly T. Hickel, CEO of Spring Creek Capital, Inc., "Getting Jennifer on the AllStem team represents a major step in our ability to execute our novel business plan. Two of our four major divisions at AllStem will be licensing stem cell technology and intellectual property around the globe, and there is no one better or more experienced to help guide us through the regulatory and contractual arena... we are thrilled with our latest team member."

AllStem has offices in New York and the Orlando, Florida area. The company mission is to provide cellular-based lifesaving or life enhancing options to all individuals seeking assurances that they will be able to take advantage of current and future medical advancements in the field of stem cell sciences. AllStem has developed a unique business model centering on personalized medicine and the advancement of stem cell sciences. The plan utilizes four distinct areas of focus that have been proven to be the most lucrative and successful in the field.

Spring Creek Capital recently elected to be treated as a business development corporation (BDC) under the Investment Company Act of 1940 and will focus on portfolio investments in companies developing cutting edge solutions for the healthcare market.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risks that could cause actual performance and results of operations to differ materially from those anticipated. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new ventures, as well as other factors set forth in Spring Creek Capital's most recently filed Form 10-K and Form 10-Q reports. The forward-looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. Spring Creek Capital assumes no obligation to update the statements contained in this release.


Publication Contributing Sources

Similar Stocks and Investing Publications